Navigation Links
Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History
Date:2/5/2008

December 29, December 31,

2007 2006 2007 2006

Tax

benefit

on a

GAAP

basis $1,162 46.4% $826 36.7% $893 38.1% $1,463 58.3%

Amortization

of

purchased

intan-

gibles (1,375) (1,289) (5,033) (4,822)

Litigation

/make-

whole

provision (2) (11) 33 (179)

CEO

transition

costs

and other - (47) - (456)

Share-

based

compen-

sation

expense (2,107) (333) (3,510) (1,752)

In-

process

research

and

develop-

ment - (448) - (448)

Tax expense

on a

non-GAAP

basis $(2,322) -26.0% $(1,302) -15.2% $(7,617) -29.0% $(6,194) -23.2%

The following tables reconcile the Guidance on a GAAP and Non-GAAP basis for the periods shown below:

THORATEC CORPORATION

Reconciliation of GAAP to Non-GAAP Forward-Looking Guidance

(Unaudited)

(in thousands, except for per share data)

Gross margin For the Fiscal

Year Ended 2008

From To

(in thousands)

Gross profit on a GAAP basis 58% 59%

Share-based compensation expense:

- Cost of product sales 1% 1%

Gross profit on a non-GAAP basis 59% 60%

Operating Income For the Fiscal'/>"/>

SOURCE Thoratec Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Thoratec Presentation at JP Morgan Conference to be Webcast
2. Thoratec Announces Appointment of Steven H. Collis to Board of Directors
3. Thoratec Presentation at Bear Stearns Conference To Be Webcast
4. Thoratec Announces HeartMate II(R) PMA Will be Reviewed by FDA Advisory Panel
5. Rochester Medical Reports 31% Increase in Branded Sales Resulting in 9% Overall Sales Growth for the First Quarter
6. Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year
7. CuraGen Reports Fourth Quarter and Year End 2007 Financial Results
8. Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20%
9. Phosphagenics Reports Superior Pre-clinical Cholesterol Results from APA-01 and Atorvastatin Combination
10. Viventia Biotech to Explore Strategic Alternatives - Reports Positive Pivotal Phase III Interim Efficacy Data
11. Millennium Biotechnologies Group Reports 40% Sales Increase for Resurgex Product Line in Greek Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... May 6, 2015   University of Maryland (UM) ... today the signing of an exclusive option by Biomecite ... (UMB) to develop diagnostics to detect inflammatory bowel diseases ... (CD). Drs. Florian Fricke and James ... with the University of Maryland School of Medicine,s Institute ...
(Date:5/6/2015)... May 6, 2015 ... specialist, announced today that it has signed an agreement ... PEIX ) for the delivery of an industrial scale ... the consumption of water, energy and emissions ... This project is fully aligned ...
(Date:5/5/2015)... Frederick, MD (PRWEB) May 05, 2015 ... solutions provider released FreezerPro® version 7, the latest major ... management software., Upgrade is a ... Revamped UI succeeds in enhancing users experience, while also ... overall performance, reduces system requirements , Download ...
(Date:5/5/2015)...  23andMe, Inc., the leading personal genetics company, today ... in collaboration with Pfizer Inc. The companies aim ... commonly known as lupus, into the study to help ... also in collaboration with the Lupus Research Institute, and ... Approximately 1.5 million people in the U.S. suffer ...
Breaking Biology Technology:Biomecite Diagnostics Signs Option Agreement with UM Baltimore to Develop Tools to Detect Inflammatory Bowel Diseases 2Biomecite Diagnostics Signs Option Agreement with UM Baltimore to Develop Tools to Detect Inflammatory Bowel Diseases 3Whitefox Signs Agreement With Pacific Ethanol Inc. 2RURO Releases version 7 of FreezerPro® software 223andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 223andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 3
... Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced ... during the 4th Annual BIO Investor Forum,on Thursday, ... The presentation,will be webcast from The Palace Hotel, ... Relations tab at http://www.alexza.com or, http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=ALXA&item_id=16576 ...
... Dr. Brad Thompson, President,and CEO of Oncolytics Biotech ... overview of the Company at the 15th annual ... 9 at 9 a.m. The conference,will be held ... October 7-9,2007. About Oncolytics Biotech Inc. ...
... a special eye for the,details hidden from casual view, ... Aspinall. Photographs of architectural details from beaches,to buildings and ... The,collection includes images from seven different countries., Well-known ... of Genzyme Genetics, is also a talented artist whose ...
Cached Biology Technology:The 4th Annual BIO Investor Forum to Webcast Alexza's Corporate Presentation 2Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe 2An Uncommon Eye: Photography Exhibit by Biotechnology Executive at BHCC Gallery 2
(Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... revenues for Q1 2015 attributed to somewhat higher than ... company in the year-end report 2014 that revenues for ... MSEK that the company reported for Q4 2014. The ... continue to be negative. The complete interim report will ...
(Date:3/31/2015)...  Elephant Talk Communications Corp. (NYSE MKT: ETAK) ("Elephant ... Defined Network Architecture (ET Software DNA® 2.0) platforms and ... $20.4 million for the year ended December 31, 2014 ... year ended December 31, 2013. At ... its multi-year transition away from its legacy landline business ...
(Date:3/24/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has ... Market 2015-2019" report to their offering. ... grow at a CAGR of 23.5 percent over the ... scenario and the growth prospects of the Global Iris ... market size, the report considers the revenue generated from ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... , Putnam Valley, NY. (Sept. 17 2013) Vaginal ... can lead to "stress urinary incontinence" (SUI), a condition ... have had babies via vaginal delivery. Many current treatments, ... , Seeking better methods to alleviate SUI, researchers carried ...
... -- Carbonation, an essential component of popular soft drinks, ... difficult for the brain to determine the difference between ... in Gastroenterology , the official journal of the ... the right combination of carbonation and artificial sweeteners can ...
... largest research organization launches today two virtual Joint Research ... Biological Sciences (NCBS), the Jawaharlal Nehru Center for Advanced ... (IISc). The two centers will facilitate scientific ... the fields of biology, life science and materials science. ...
Cached Biology News:Mesenchymal stem cell transplantation may heal a mother's childbirth injury 2Carbonation alters the mind's perception of sweetness 2RIKEN and leading Indian institutions launch Joint Research Centers 2
... is chromatographically purified from egg white. The extinction ... product is in 10 mM phosphate-buffered saline, ... albumin, 0.05% sodium azide and 50% glycerol. Avidin ... conjugate is purified by molecular sieving ...
in vitro Translation, Accessory Products...
Request Info...
... derivatives that have mutations in both the ... genes, which greatly enhances disulfide bond formation ... expression in Origami(DE3) yielded 10-fold more active ... overall expression levels were similar (1). Origami ...
Biology Products: